UBS upgrades IMCD stock rating to Neutral from Sell on valuation

UBS upgraded chemical distributor IMCD NV to Neutral from Sell, citing the stock's approximately 20% year-to-date decline which has pushed its valuation to a historic trough multiple of 13.5x FY2026 estimated EV/EBITA, now deemed to reflect existing sector pressures. However, the firm simultaneously lowered its price target to EUR122 and reduced FY2025-2026 earnings forecasts by 2-6% below consensus, reflecting continued concerns over an earnings reset, anticipated volume and gross profit deterioration, and broader industry challenges.

Analysis

UBS has upgraded IMCD NV to Neutral from Sell, a move driven primarily by valuation rather than improving fundamentals. The upgrade follows a significant 20% year-to-date decline in IMCD's share price, which has pushed the stock to what UBS describes as a historic trough multiple of approximately 13.5x its FY2026 estimated EV/EBITA. Despite the rating change, the bank's underlying outlook remains cautious. This is evidenced by a concurrent reduction in the price target to EUR122.00 from EUR128.00 and a lowering of adjusted EBITA forecasts for fiscal years 2025-2026 to levels 2-6% below consensus. The downward revision reflects expectations of deteriorating volume and gross profit per unit in the second and third quarters of 2025, compounded by broader sector-wide headwinds highlighted by recent profit warnings from industry peers. The action suggests UBS believes the current valuation now adequately reflects these earnings risks, representing a shift from 'overvalued' to 'fairly valued' in a challenging environment.

Key Decisions for Investors

• View the upgrade to Neutral not as a bullish catalyst, but as a valuation call suggesting the market may have already priced in the negative outlook after the 20% stock decline.
• Exercise caution due to the simultaneous price target reduction and downward earnings revisions, which signal continued fundamental weakness and sector-wide pressures ahead.
• Closely monitor IMCD's upcoming volume and gross profit data for Q2-Q3 2025, as any performance better or worse than the newly lowered forecasts will be a key determinant of future stock performance.